Allogeneic transplantation for ALL in adults

被引：21

作者：

Stein, A. ^{[1
]}

Forman, S. J. ^{[1
]}

机构：

[1] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopeoet Cell Transplantat, Duarte, CA 91010 USA

来源：

BONE MARROW TRANSPLANTATION | 2008年 / 41卷 / 05期

关键词：

ALL; transplant regimens; reduced-intensity transplant;

D O I：

10.1038/bmt.2008.1

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Allogeneic transplantation is an effective treatment for adult patients with high-risk ALL, including patients in first or second remission. Although only a few studies have evaluated the optimal transplant regimens, the data would suggest that a TBI-based regimen results in better disease control. Although not as potent as it is in other hematologic malignancies, the GVL effect is an important component of achieving cure of ALL. Because of the toxicity of the fully ablative regimen, reduced-intensity transplants are being explored in older patients with ALL when the prognosis is especially poor with standard chemotherapy.

引用

页码：439 / 446

页数：8

共 60 条

[1] Haematopoietic cell transplantation as immunotherapy [J].

Appelbaum, FR .

NATURE, 2001, 411 (6835) :385-389

[2]

APPELBAUM FR, 1997, LEUKEMIA, V11, P15

[3] Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease [J].

Arnold, R ;

Massenkeil, G ;

Bornhäuser, M ;

Ehninger, G ;

Beelen, DW ;

Fauser, AA ;

Hegenbart, U ;

Hertenstein, B ;

Ho, AD ;

Knauf, W ;

Kolb, HJ ;

Kolbe, K ;

Sayer, HG ;

Schwerdtfeger, R ;

Wandt, H ;

Hoelzer, D .

LEUKEMIA, 2002, 16 (12) :2423-2428

[4] Unrelated donor allogeneic transplantation for adult acute lymphoblastic leukemia: a review [J].

Bachanova, V. ;

Weisdorf, D. .

BONE MARROW TRANSPLANTATION, 2008, 41 (05) :455-464

[5] Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols [J].

Barry, Elly ;

DeAngelo, Daniel J. ;

Neuberg, Donna ;

Stevenson, Kristen ;

Loh, Mignon L. ;

Asselin, Barbara L. ;

Barr, Ronald D. ;

Clavell, Luis A. ;

Hurwitz, Craig A. ;

Moghrabi, Albert ;

Samson, Yvan ;

Schorin, Marshall ;

Cohen, Harvey J. ;

Sallan, Stephen E. ;

Silverman, Lewis B. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :813-819

[6]

BLUME KG, 1993, BLOOD, V81, P2187

[7]

BLUME KG, 1987, BLOOD, V69, P1015

[8] Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia [J].

Brüggemann, M ;

Raff, T ;

Flohr, T ;

Gökbuget, N ;

Nakao, M ;

Droese, J ;

Lüschen, S ;

Pott, C ;

Ritgen, M ;

Scheuring, U ;

Horst, HA ;

Thiel, E ;

Hoelzer, D ;

Bartram, CR ;

Kneba, M .

BLOOD, 2006, 107 (03) :1116-1123

[9] Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia [J].

Carpenter, Paul A. ;

Snyder, David S. ;

Flowers, Mary E. D. ;

Sanders, Jean E. ;

Gooley, Theodore A. ;

Martin, Paul J. ;

Appelbaum, Frederick R. ;

Radich, Jerald P. .

BLOOD, 2007, 109 (07) :2791-2793

[10] Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia [J].

Cavé, H ;

ten Bosch, JV ;

Suciu, S ;

Guidal, C ;

Waterkeyn, C ;

Otten, J ;

Bakkus, M ;

Thielemans, K ;

Grandchamp, B ;

Vilmer, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :591-598

← 1 2 3 4 5 6 →